The global pandemic's onset in 2020 caused profound disruptions in pharmaceutical supply chains, upending established systems and introducing ongoing challenges. These challenges have been further exacerbated by rising geopolitical tensions, intensifying competition, fluctuating demand and supply dynamics, evolving customer needs, and stringent regulatory requirements. Together, these factors have created a complex landscape of obstacles for drug sponsors and manufacturers to navigate.
Supply Chain Changing Dynamics & Disruptions
-
Effects of Geopolitical Strain on Global Pharmaceutical Supply Chain and Drug Shortages
Emerging geopolitical risks are increasingly threatening global supply chains, particularly those critical to the production of essential and life-saving drugs. For example, export bans imposed by certain countries can hinder pharmaceutical companies' ability to distribute their products internationally, potentially leading to shortages and disruptions in global drug availability. These geopolitical tensions create uncertainty and can severely impact company strategies and supply chain stability.
Key geopolitical hotspots, such as the Middle East, Northern Europe, and Asia, further exacerbate this instability. Conflicts or political unrest in these regions can affect both the demand and supply of pharmaceutical products, increasing variability in supply chains. This heightened instability underscores the need for pharmaceutical companies to be more agile and adaptable. Developing strategies to mitigate risks, diversify supply sources, and enhance overall resilience is crucial to maintaining a steady flow of essential medications in an unpredictable global landscape.
-
Impact of Covid 19
The COVID-19 pandemic revealed the vulnerabilities of relying heavily on a single geographic source for essential drugs and medical supplies. The crisis demonstrated how this dependency could lead to significant supply chain disruptions, with global trade restrictions, lockdowns, and surging demand causing shortages and delays. This situation highlighted the urgent need for more diversified and resilient supply chains to mitigate risks and ensure a more reliable distribution of critical healthcare resources.
-
High Dependency on Imports from China
Disruptions in China have had significant global repercussions on the availability of products and medications. Many pharmaceutical manufacturers rely heavily on China for active pharmaceutical ingredients (APIs), raising concerns about potential shortages of crucial medications worldwide. This reliance on China for APIs highlights the vulnerabilities associated with supply chain disruptions originating from this region.
Pharmaceutical trade is currently more global than most other industries, but a shift towards regionalization may be underway. Companies often source critical materials from a single region—China—making them susceptible to shortages during natural disasters or local conflicts. Approximately 40% of pharmaceutical trade occurs within a specific region, compared to an average of 50% for other industries.
Moreover, concerns persist about the integrity of China’s clinical trials and regulatory standards. The country’s pharmaceutical industry faces scrutiny due to a relatively lax regulatory environment and inadequate oversight by the Chinese government. The regulatory framework is under-resourced, struggling to effectively monitor the thousands of drug manufacturers operating within the country. Even if regulatory oversight were to become a higher priority, the sheer volume of manufacturers presents a significant challenge.
Read more: Winning in Implantable Medical Devices Market: Pharma’s Next Frontier
This regulatory gap has led to several drug safety scandals and issues with data integrity. For example, in 2016, the China Food and Drug Administration (CFDA) reviewed 1,622 drug clinical trial programs and subsequently canceled 80% of drug applications after uncovering evidence of fraudulent data reporting and incomplete submissions, among other irregularities.
These issues underscore the broader challenges faced by both U.S. and Chinese health regulators in ensuring the safety and efficacy of pharmaceuticals. The lack of reliable data from China complicates the regulatory process, raising concerns about the stability of the global supply chain as well as the integrity of drug approval processes.
-
Mergers and Acquisitions Pose a Risk for Cyber Security Attacks
Mergers and acquisitions (M&A) are common in the pharmaceutical industry, and while they can drive business growth and market expansion, they also introduce significant security risks. The API and biologics sectors, in particular, are highly dynamic and prone to M&A activity. These transitions can disrupt established processes by altering leadership, strategic focus, and operational practices, creating vulnerabilities that compromise the security of confidential data and potentially disrupt the supply chain. For example, a security lapse during an M&A could threaten the integrity of APIs, which are essential for drug manufacturing.
Additionally, the pharmaceutical supply chain is influenced by fluctuating consumer demands, driven by factors such as seasonal variations, market trends, health crises like COVID-19, and promotional events. This volatility complicates demand forecasting, inventory management, and production planning, increasing the risk of shortages and delays in the availability of essential medications. As a result, these disruptions can affect the entire supply chain, from API production to the delivery of finished drugs to patients.
-
Stringent Regulations
Stringent regulations governing pharmaceutical manufacturing have made supply chain issues a significant concern for the industry. Every active ingredient, excipient, reagent, and packaging component in a pharmaceutical product must first be validated by regulatory authorities. In contrast, when a consumer goods manufacturer encounters concerns about sourcing an ingredient or packaging material, they can often substitute it with an alternative much more easily.
While these regulations are crucial for ensuring the safety and efficacy of the final product, implementing compliance updates to new regulations requires considerable time and can disrupt operational flow. In the United States in 2013, the Drug Supply Chain Security Act was passed and gradually implemented through the end of 2023, which mandated stringent tracking processes. This requirement necessitated a comprehensive overhaul of tracking, recording, and reporting systems, consuming significant time and resources.
Given these potential areas for supply chain disruptions, how can a pharmaceutical company develop the resilience and capability to navigate these challenges—transforming them from potential waves into mere ripples?
Key Strategies Reshaping Pharma Supply Chain
-
Diversification of Production Sources
Diversifying production sources through dual-sourcing strategies offers significant advantages for the pharmaceutical industry. By sourcing critical raw materials from multiple suppliers, enterprises can mitigate the risks associated with relying on a single source, such as disruptions from natural disasters, political instability, or supplier-specific issues. This approach strengthens supply chain resilience, ensuring a more stable and continuous supply of essential materials.
Dual sourcing also increases negotiation leverage, enabling better pricing and contract terms, and fosters strategic flexibility, allowing enterprises to adapt to changes in demand or market conditions. Additionally, it supports regulatory compliance and can drive improvements in raw material quality and innovation. Overall, dual sourcing contributes to a more robust and adaptable supply chain, ensuring the reliable production and availability of crucial medications for patients.
-
Expanding Domestic Production and the Use of Innovative Production Techniques
Expanding domestic production and adopting innovative manufacturing techniques offer substantial benefits for strengthening supply chains. Shifting from global to regional supply networks can yield significant cost savings and reduce dependency on single suppliers, especially those located in regions with geopolitical risks, such as China. This transition involves sourcing high-volume intermediates and APIs from qualified domestic suppliers, which helps mitigate risks associated with international supply disruptions.
Read more: Sustainability Efforts by the Pharmaceutical Industry
Regionalizing the supply chain allows for greater control and flexibility, reducing the impact of global disruptions and shortening lead times. This approach not only enhances reliability but also supports local economies and can lead to more efficient production processes through the adoption of advanced technologies. Ultimately, increasing domestic production and leveraging innovative methods contribute to a cost-effective supply chain, ensuring a stable and secure supply of essential materials.
By diversifying sourcing strategies, companies can reduce their exposure to single sources and other supply chain risks. Options include reverting to domestic production, nearshoring, or exploring new offshore locations. In 2018, 38% to 60% of international pharmaceutical trade, valued between $236 billion and $377 billion, was considered for potential sourcing diversification.
-
Fostering Digital Supply Management Systems
To navigate the complexities of modern supply chains, pharmaceutical companies are increasingly adopting digital supply management systems. Advanced planning technologies and sophisticated algorithms enable real-time, data-driven decision-making, providing comprehensive visibility across the entire supply chain. This enhanced visibility supports proactive management, allowing companies to adapt to changes in demand & supply, thereby preventing costly delays and ensuring timely delivery of medications to patients.
Digitizing procurement processes and utilizing e-bidding platforms are also crucial. These tools reduce intermediaries, lower costs, and leverage competitive pricing while improving communication and collaboration with suppliers. This shift towards digital operations streamlines procurement and enhances transparency, promoting a more proactive approach.
Automating sales and operations planning (S&OP) further refines the process by reducing reliance on manual data handling and multiple iterations. Real-time insights into inventory, supply levels, demand forecasts, and production capabilities enable faster, more accurate decision-making. These technological advancements help companies quickly address disruptions and maintain efficient operations.
AI-powered technologies are increasingly transforming supply chains by enhancing visibility, agility, and decision-making capabilities. These advancements offer a comprehensive view of the entire supply chain, enabling more responsive and informed actions. However, integrating such technologies introduces security concerns that need to be addressed in order to protect sensitive data and ensure system integrity.
-
Cooperation Between Countries
International cooperation is crucial for building and sustaining a robust global distribution network. By partnering with stakeholders across various countries, pharmaceutical companies can improve the efficiency and resilience of their supply chains. This collaboration includes forming strategic agreements, such as long-term contracts and input-linked pricing, which help manage costs and mitigate the effects of global inflation. Such cooperative efforts enhance cost efficiency, stability, and reliability in the distribution of pharmaceuticals, ensuring that essential medications remain consistently available despite economic and geopolitical challenges.
Read more: Data and Analytics in Healthcare: Benefits and its Importance
Conclusion
The pharmaceutical industry faces significant challenges in addressing supply chain disruptions. Adhering to all regulations and staying informed about upcoming regulatory changes is essential. Maintaining an uninterrupted, visible, and traceable chain of custody—from sourcing raw materials to manufacturing, wholesale distribution, and delivery to patients—is crucial for ensuring consumer confidence in medications and therapies.
Nonetheless, lessons learned from recent crises, combined with strategic investments in diversification, technology, and collaboration, provide a path forward. By adopting these strategies, the industry can enhance its resilience and better meet the demands of a rapidly evolving landscape.
These strategies are not merely one-time solutions but are integral to an ongoing effort to build more robust and adaptable supply chains. The ultimate objective is to ensure that patients around the world have consistent access to essential medications, even amidst unforeseen challenges.
About SG Analytics
SG Analytics (SGA) is an industry-leading global data solutions firm providing data-centric research and contextual analytics services to its clients, including Fortune 500 companies across BFSI, Technology, Media & Entertainment, and Healthcare sectors. Established in 2007, SG Analytics is a Great Place to Work® (GPTW) certified company with a team of over 1200 employees and a presence across the U.S.A., the UK, Switzerland, Poland, and India.
A leader in the healthcare domain, SG Analytics assists healthcare companies in leveraging the power of information. Contact us today if you are in search of efficient Healthcare solutions to make sound business decisions.
Apart from being recognized by reputed firms such as Gartner, Everest Group, and ISG, SGA has been featured in the elite Deloitte Technology Fast 50 India 2023 and APAC 2024 High Growth Companies by the Financial Times & Statista.
